Analysts Set Simulations Plus, Inc. (NASDAQ:SLP) Price Target at $25.00

Simulations Plus, Inc. (NASDAQ:SLP) has received a consensus rating of “Hold” from the ten brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $25.00.

Several equities research analysts have recently commented on SLP shares. Citigroup restated a “market perform” rating on shares of Simulations Plus in a research note on Tuesday, January 6th. TD Cowen restated a “hold” rating on shares of Simulations Plus in a research report on Thursday, January 8th. BTIG Research downgraded shares of Simulations Plus from a “buy” rating to a “neutral” rating in a report on Thursday, December 18th. Zacks Research lowered shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 2nd. Finally, KeyCorp reissued a “sector weight” rating on shares of Simulations Plus in a report on Wednesday, October 29th.

Institutional Trading of Simulations Plus

Institutional investors have recently modified their holdings of the business. Tributary Capital Management LLC lifted its holdings in Simulations Plus by 214.7% in the third quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock valued at $17,134,000 after acquiring an additional 775,704 shares during the period. Ameriprise Financial Inc. grew its stake in shares of Simulations Plus by 25.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock worth $15,277,000 after purchasing an additional 176,747 shares during the period. First Light Asset Management LLC increased its holdings in shares of Simulations Plus by 115.0% in the 3rd quarter. First Light Asset Management LLC now owns 767,760 shares of the technology company’s stock valued at $11,570,000 after purchasing an additional 410,603 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Simulations Plus by 127.5% in the fourth quarter. Marshall Wace LLP now owns 569,783 shares of the technology company’s stock valued at $10,387,000 after purchasing an additional 319,301 shares during the period. Finally, Stephens Investment Management Group LLC boosted its holdings in Simulations Plus by 30.8% during the fourth quarter. Stephens Investment Management Group LLC now owns 513,728 shares of the technology company’s stock worth $9,365,000 after buying an additional 120,888 shares in the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

Simulations Plus Stock Up 1.5%

Shares of Simulations Plus stock opened at $12.29 on Wednesday. Simulations Plus has a 52 week low of $12.00 and a 52 week high of $37.67. The firm’s 50 day moving average is $18.19 and its two-hundred day moving average is $16.54. The firm has a market capitalization of $247.61 million, a P/E ratio of -3.84 and a beta of 1.12.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Thursday, January 8th. The technology company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.05). The company had revenue of $18.42 million for the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a positive return on equity of 14.02% and a negative net margin of 81.66%.During the same quarter in the prior year, the firm posted $0.17 EPS. As a group, research analysts expect that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

About Simulations Plus

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.